HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model

International Journal of Cancer

Volumn 126, Issue 3, 2010, Pages 733-742

  Kothari, Vishal ^a   Joshi, Ganesh ^a   Nama, Srikanth ^b   Somasundaram, Kumaravel ^b   Mulherkar, Rita ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Adenoviral vector; Cancer gene therapy; HDAC inhibitors; Prodrug activation; Valproic acid

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; THYMIDINE KINASE; VALPROIC ACID; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HERPES SIMPLEX VIRUS; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUICIDE GENE THERAPY; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME;

ADENOVIRUSES, HUMAN; ANIMALS; BYSTANDER EFFECT; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEFECTIVE VIRUSES; FEMALE; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, NUDE; PRODRUGS; SIMPLEXVIRUS; THYMIDINE KINASE; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73449102542     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24700     Document Type: Article

References (53)

1. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2:148-64. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=10894261.
2. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list- uids=8221662.
3. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993;4:725-31. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=8186287.
4. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-99. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=10945596.
5. Lumniczky K, Safrany G. Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol Oncol Res 2006;12:118-24. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 16799716.
6. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. In.uence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2002;2:307-22. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list- uids=12189718.
7. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007;9:833-42. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed &dopt=Citation&list-uids=17721874.
8. Jager L, Ehrhardt A. Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 2007;7:272-83. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=17969560.
9. Lonberg-Holm K, Philipson L. Early events of virus-cell interaction in an adenovirus system. J Virol 1969;4:323-38. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=4898584.
10. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006;66:7237-44. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=16849572.
11. McDonald D, Stockwin L, Matzow T, Blair Zajdel ME, Blair GE. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cells. Gene Ther 1999;6:1512-9. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 10490760.
12. Xie J, Chiang L, Contreras J, Wu K, Garner JA, Medina-Kauwe L, Hamm-Alvarez SF. Novel .ber-dependent entry mechanism for adenovirus Serotype 5 in lacrimal acini. J Virol 2006;80:11833-51. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=16987972.
13. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998;9:2363-73. Available from: www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=9829535.
14. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-19. Available from: www.ncbi.nlm. nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation &list-uids=8477447.
15. Suominen E, Toivonen R, Grenman R, Savontaus M. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. J Gene Med 2006;8:1223-31. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=16941521.
16. Li D, Duan L, Freimuth P, O'Malley BW, Jr. Variability of adenovirus receptor density in.uences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999;5:4175-81. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=10632357.
17. Fedor MJ, Daniell E. Acetylation of histone-like proteins of adenovirus type 5. J Virol 1980;35:637-43. Available from: www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=7420537.
18. Dery CV, Toth M, Brown M, Horvath J, Allaire S, Weber JM. The structure of adenovirus chromatin in infected cells. J Gen Virol 1985;66 (Part 12):2671-84. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list- uids=4067582.
19. Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol 2002;80:363-78. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db= PubMed&dopt=Citation&list-uids=12123289.
20. Dario LS, Rosa MA, Mariela E, Roberto G, Caterina C. Chromatin remodeling agents for cancer therapy. Rev Recent Clin Trials 2008;3: 192-203. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd =Retrieve&db= PubMed&dopt=Citation&list-uids=18782077.
21. Moradei O, Vaisburg A, Martell RE. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Top Med Chem 2008;8:841-58. Available from: ww.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 18673170.
22. VanOosten RL, Earel JK, Jr, Grif.th TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 2006;13:628-32. Available from: ww.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 16456549.
23. Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 2007;14:327-34. Available from: www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=17186014.
24. Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Sakata H, Matsushita K, Komatsu A, Brooks R, Ochiai T. Role of histone deacetylase inhibitor in adenovirusmediated p53 gene therapy in esophageal cancer. Anticancer Res 2008;28:665-71. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=18507005.
25. Asklund T, Appelskog IB, Ammerpohl O, Ekstrom TJ, Almqvist PM. Histone deacetylase inhibitor 4-phenylbutyrate modulates glial .brillary acidic protein and connexin 43 expression, and enhances gapjunction communication, in human glioblastoma cells. Eur J Cancer 2004;40:1073-81. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=15093585.
26. Ammerpohl O, Thormeyer D, Khan Z, Appelskog IB, Gojkovic Z, Almqvist PM, Ekstrom TJ. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 2004;324:8-14. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=15464975.
27. Kobayashi M, Okada T, Murakami T, Ozawa K, Kobayashi E, Morita T. Tissuetargeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems. Urology 2007;70:1230-6. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=18158067.
28. Fan S, Maguire CA, Ramirez SH, Bradel-Tretheway B, Sapinoro R, Sui Z, Chakraborty-Sett S, Dewhurst S. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005;125:23-33. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=15737413.
29. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression pro.les in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-10. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=18628465.
30. Mulherkar R, Goud AP, Wagle AS, Naresh KN, Mahimkar MB, Thomas SM, Pradhan SA, Deo MG. Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Lett 1997;118:115-21. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=9310268.
31. Ambade A, Mulherkar R. Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model. Cancer Lett 2008;272:316-24. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=18762367.
32. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simpli.ed system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-14. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=9482916.
33. Colbere-Garapin F, Chousterman S, Horodniceanu F, Kourilsky P, Garapin AC. Cloning of the active thymidine kinase gene of herpes simplex virus type 1 in Escherichia coli K-12. Proc Natl Acad Sci USA 1979;76:3755-9. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=226978.
34. Gueret V, Negrete-Virgen JA, Lyddiatt A, Al-Rubeai M. Rapid titration of adenoviral infectivity by flow cytometry in batch culture of infected HEK293 cells. Cytotechnology 2002;38:87-97. Available from: www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list- uids=19003090.
35. Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther 2003;10:501-8. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=12833130.
36. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007;28:4-41. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 17306358.
37. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=3019523.
38. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Yla-Herttuala S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004;10:967-72. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=15509514.
39. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389-401. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=11096443.
40. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996;93:3525-9. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 8622970.
41. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001;61:3022-6. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=11306482.
42. Fick J, Barker FG, II, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995;92:11071-5. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=7479939.
43. Gentry BG, Boucher PD, Shewach DS. Hydroxyurea induces bystander cytotoxicity in cocultures of herpes simplex virus thymidine kinase-expressing and nonexpressing HeLa cells incubated with ganciclovir. Cancer Res 2006;66:3845-51. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=16585212.
44. Auer D, Reimer D, Porto V, Fleischer M, Roessler J, Wiedemair A, Marth C, Muller-Holzner E, Daxenbichler G, Zeimet AG. Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer. Breast Cancer Res Treat 2009;116:103-11. Available from: www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=18618240.
45. VanOosten RL, Earel JK, Jr, Grif.th TS. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 2007;12:561-71. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=17195089.
46. Michaelis M, Doerr HW, Cinatl J Jr. Valproic acid as anti-cancer drug. Curr Pharm Des 2007;13:3378-93. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 18045192.
47. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, Ramchandran R, Roberts DD. Modulation of angiogenesis by dithiolethione-modi.ed NSAIDs and valproic acid. Br J Pharmacol 2007;151:63-72. Available from: www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=17351657.
48. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007;17:647-51. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=17273746.
49. Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 1997;94:5798-803. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 9159154.
50. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 1997;4:577-85. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=9231074.
51. Cirenei N, Colombo BM, Mesnil M, Benedetti S, Yamasaki H, Finocchiaro G. In vitro and in vivo effects of retrovirusmediated transfer of the connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy. Gene Ther 1998;5:1221-6. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=9930323.
52. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC, Gahrton G, Smith CI. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997;57:1523-8. Available from: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=9108455.
53. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz S E, Hovelmann S, Gottlicher M, Knuth A, Jager E. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-82. Available from: www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 17579623.